Modulation of cGMP-signalling to Prevent Retinal Degeneration
(2019) In RSC Drug Discovery Series 2019-January(66). p.88-98- Abstract
In the photoreceptors of the retina, the second-messenger molecule cyclic guanosine monophosphate (cGMP) occupies centre stage in the phototransduction cascade. Remarkably, cGMP is also involved in hereditary photoreceptor degeneration caused by a variety of different genetic insults. This provides an entry point for the development of inhibitory cGMP analogues for a mutation-independent treatment. Here, we outline how cGMP signalling can be targeted for the treatment of retinal degeneration, how inhibitory cGMP analogues may be designed and formulated, and how test systems of rising complexity can be used to identify new compounds with photoreceptor neuroprotective properties. In this context, we cite the European Union-funded... (More)
In the photoreceptors of the retina, the second-messenger molecule cyclic guanosine monophosphate (cGMP) occupies centre stage in the phototransduction cascade. Remarkably, cGMP is also involved in hereditary photoreceptor degeneration caused by a variety of different genetic insults. This provides an entry point for the development of inhibitory cGMP analogues for a mutation-independent treatment. Here, we outline how cGMP signalling can be targeted for the treatment of retinal degeneration, how inhibitory cGMP analogues may be designed and formulated, and how test systems of rising complexity can be used to identify new compounds with photoreceptor neuroprotective properties. In this context, we cite the European Union-funded DRUGSFORD project and provide an example for the efficacy of a specific cGMP analogue to prevent photoreceptor loss and preserve retinal function.
(Less)
- author
- Marigo, Valeria ; Ekström, Per LU ; Schwede, Frank ; Rentsch, Andreas and Paquet-Durand, François LU
- organization
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- in
- RSC Drug Discovery Series
- volume
- 2019-January
- issue
- 66
- pages
- 11 pages
- publisher
- Royal Society of Chemistry
- external identifiers
-
- scopus:85056596719
- ISSN
- 2041-3203
- DOI
- 10.1039/9781788013666-00088
- language
- English
- LU publication?
- yes
- id
- 9dc6a528-cc57-4f98-9579-980482c92b22
- date added to LUP
- 2018-11-26 12:53:13
- date last changed
- 2022-04-25 19:24:21
@article{9dc6a528-cc57-4f98-9579-980482c92b22, abstract = {{<p>In the photoreceptors of the retina, the second-messenger molecule cyclic guanosine monophosphate (cGMP) occupies centre stage in the phototransduction cascade. Remarkably, cGMP is also involved in hereditary photoreceptor degeneration caused by a variety of different genetic insults. This provides an entry point for the development of inhibitory cGMP analogues for a mutation-independent treatment. Here, we outline how cGMP signalling can be targeted for the treatment of retinal degeneration, how inhibitory cGMP analogues may be designed and formulated, and how test systems of rising complexity can be used to identify new compounds with photoreceptor neuroprotective properties. In this context, we cite the European Union-funded DRUGSFORD project and provide an example for the efficacy of a specific cGMP analogue to prevent photoreceptor loss and preserve retinal function.</p>}}, author = {{Marigo, Valeria and Ekström, Per and Schwede, Frank and Rentsch, Andreas and Paquet-Durand, François}}, issn = {{2041-3203}}, language = {{eng}}, number = {{66}}, pages = {{88--98}}, publisher = {{Royal Society of Chemistry}}, series = {{RSC Drug Discovery Series}}, title = {{Modulation of cGMP-signalling to Prevent Retinal Degeneration}}, url = {{http://dx.doi.org/10.1039/9781788013666-00088}}, doi = {{10.1039/9781788013666-00088}}, volume = {{2019-January}}, year = {{2019}}, }